Diets · Metabolic & Cardiometabolic
time-restricted eating improves glycemic control
In plain terms: Does a daily eating window improve diabetic blood sugar?
Part of: 🥗 time-restricted eating
Yes, but the benefit is small and doesn't clearly beat simply matching calories.
📅 Last reviewed: 2026-07-14 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
What the evidence shows
TRE modestly improves glycemia (HbA1c ~-0.43%) and BP in type 2 diabetes - real but clinically small, with no clear superiority over calorie-matched comparators.
The evidence (20)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Mohammadpour S et al 2026 · study_type: RCT | RCT | mixed | low | 24-week RCT in 120 T2D adults: both calorie-carb restriction alone (CCR) and CCR+8h TRE (IFCCR) improved outcomes with adjustment for HbA1c change, but the trial's primary endpoints were eating-disorder psychopathology/distress, not HbA1c i |
| Andriessen 2022 · Diabetologia | RCT | supports | moderate | Three weeks of TRE improved 24h glucose and time-in-range in free-living T2DM adults, though without changes in insulin sensitivity or hepatic glycogen ↩ SUPERSEDED — pooled in the review above, counted once |
| Chen J et al 2026 · study_type: meta-analysis | meta-analysis | supports | moderate | Meta-analysis of 14 RCTs (899 T2D/prediabetes patients): intermittent fasting (including TRE protocols) reduced HbA1c more than ad libitum eating (SMD -0.64), with effects on HbA1c similar to continuous energy restriction (CERD). |
| Doraisamy 2026 · Nutr Rev | meta-analysis | supports | moderate | SR of human+rodent TRF: consistent improvements in glycemic control including HbA1c in T2DM |
| Sharma 2023 · TouchREVIEWS Endocrinol | meta-analysis | contradicts | moderate | SR/MA of intermittent fasting found improved glycemic control and HbA1c reductions in T2DM over the short term |
| Molani-Gol R et al] # corrected 2026-08-17 from PubMed; was [(TRE-T2D umbrella MA) 2026 · Nutr Res | meta-analysis | supports | moderate | Umbrella MA (9 MAs/15 RCTs/n=6386 T2D): HbA1c -0.43%, FG -7.5 mg/dL, SBP -4 mmHg |
| Afif CP et al 2026 · study_type: animal | animal | supports | moderate | Mouse model of OSA-associated dysglycemia: 9h/day TRE reduced fasting glucose and prevented glucose-tolerance-test AUC increases seen with ad-lib feeding; effect linked to improved pancreatic insulin secretion, not reported as HbA1c. |
| Obermayer 2022 · Diabetes Care | RCT | supports | moderate | Intermittent fasting safely ameliorated glycemic control while reducing total daily insulin dose and body weight in insulin-treated T2DM |
| Rovira-Llopis 2023 · Rev Endocr Metab Disord | meta-analysis | mixed | high | SR: timing matters; only early-TRE reduced fasting glucose in overweight/obese, suggesting HbA1c benefit is conditional on circadian alignment |
| Guo 2024 · JAMA Netw Open | RCT | supports | moderate | 5:2 intermittent-fasting meal-replacement diet lowered HbA1c more than metformin or empagliflozin short-term in early T2DM |
| Nam 2025 · Int J Mol Sci | meta-analysis | supports | moderate | [FT-verified] FT 8-RCT HbA1c MD only -0.11%; real but clinically small |
| Parr 2024 · Diabetes Res Clin Pract | RCT | supports | moderate | TRE improved glycaemic control in people with T2DM and is proposed as an alternative when individualised dietary guidance is unavailable |
| Khalafi 2024 · Diabetes Obes Metab | meta-analysis | contradicts | high | SR/MA: intermittent fasting reduced body weight/BMI vs continuous restriction but had NO effect on glycaemic markers, lipids or blood pressure |
| Kramer 2025 · J Clin Endocrinol Metab | RCT | supports | moderate | TRE improved beta-cell function and insulin resistance in overweight early-diabetes patients with beneficial adiposity changes ↩ SUPERSEDED — pooled in the review above, counted once |
| Laing KL et al 2026 · study_type: observational | observational | supports | low | 3-patient case series of T2DM adults on stable GLP-1RA following 8-10h TRE for 3 months: all 3 had HbA1c and nighttime glucose reductions plus improved time-in-range. |
| Yang 2023 · J Clin Endocrinol Metab | RCT | supports | moderate | Intermittent calorie-restricted CMNT diet achieved durable diabetes remission for at least 1yr with marked HbA1c reduction vs control |
| Kloura C et al 2026 · study_type: RCT | RCT | contradicts | moderate | RESET trial secondary analysis in 46 adults with prediabetes: no between-group difference in HbA1c or fasting glucose at 6 weeks or 3 months for 10-h TRE vs control; only a small transient nighttime-glucose benefit. |
| Lu 2026 · Diabetol Metab Syndr | meta-analysis | supports | moderate | TRE MA (12 studies, 344 T2D): HbA1c -0.32%, FBG -0.44 mmol/L, improved time-in-range |
| Liu 2025 · Nutr Res | meta-analysis | mixed | moderate | IF effectively manages blood sugar and weight in T2DM but metabolic/HbA1c benefits do NOT endure after discontinuation |
| Pavlou V, et al. (Varady) 2023 · JAMA Netw Open | RCT | supports | moderate | [FT-verified] FT JAMA n=75 TRE HbA1c -0.91% but identical to CR -0.94%; benefit via energy reduction not TRE-specific ↩ SUPERSEDED — pooled in the review above, counted once |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.